What have we learned about resistance to molecular targets, and how have serial NGS assessments with progressive biopsies helped us understand drug resistance and sequential therapies?

What have we learned about resistance to molecular targets, and how have serial NGS assessments with progressive biopsies helped us understand drug resistance and sequential therapies?

What have we learned about resistance to molecular targets, for example, in the area of ALK mutations, and how have serial NGS assessments with progressive biopsies helped our understanding of drug resistance and sequential lines of therapies to address relapses?

CLICK HERE FOR CME CREDIT

Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Samuel Klempner, MD

Samuel Klempner, MD

Director of Precision Medicine
The Angeles Clinic and Research Institute
Cedars-Sinai Medical Center
Los Angeles, CA